A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Kumar, R.
- Empaglifozin and Metformin
Authors
1 Department of Pharmacology Punjab Institute of Medical Sciences Jalandhar, Punjab, IN
Source
International Journal of Medical and Dental Sciences, Vol 5, No 1 (2016), Pagination: 1112-1113Abstract
No Abstract.Full Text
- Cardiodepressant Activity of Newer Dihydropyrimidine Derivative in Comparison to Nifedipine on Perfused Rabbits Heart
Authors
1 Department of Pharmacology, Punjab Institute of Medical Sciences (PIMS), Jalandhar, Punjab, IN
2 GMC, Patiala, Punjab, IN
3 Punjabi University, Patiala, Punjab, IN
4 Genesis Institute of Dental Sciences & Research, Ferozepur, Punjab, IN
Source
International Journal of Medical and Dental Sciences, Vol 1, No 2 (2012), Pagination: 6-14Abstract
Background: Substituted dihydropyridine calcium channel blockers are used in the treatment of cardiovascular diseases. Dihydropyridines are considered as analogue of dihydropyrimidines.
Objectives: In present study newly synthesized test compound 5- Acyl-6-methyl-4(2',3'-methylenedioxy) phenyl - 2 - S - ethyl - 1, 4- dihydropyrimidine, a dihydropyrimidine derivative was investigated with an aim to get valuable substitute for the well known dihydropyridine, Nifedipine.
Material & Methods: The Calcium Channel blocking actiuity of test compound was studied on Rabbit's Heart and its effects were compared with Nifedipine used as control.
Results: Test compound has dose-dependent negative chronotropic and negative inotropic effect on Rabbit's heart but these effects appeared at doses higher than those of Nifedipine. Test compound had no significant change in coronary flow however Nifedipine show significant increase in coronary flow at lower doses.
Conclusion: Test compound appears to be less potent myocardial depressant compared to Nifedipine. Test compound produced calcium channel blocking activity which was dose related and in order to ascertain the status of this compound as a drug, further studies are needed not only in other animals and tissue models but also in various pathophysiological models.
Keywords
Test Compound (5-Acyl-6-Methyl-4(2’,3’-Methylenedioxy) Phenyl - 2 - S - Ethyl - 1, 4-Dihydropyrimidine), DMSO (Dimethylsulphoxide), Nifedipine.Full Text
- Undetermined Teratogenic Risks by Traditional Sex Selection Drugs
Authors
1 MM Medical College & Hospital Kumarhatti-Solan, HP, IN
2 Punjab Institute of Medical Sciences Jalandhar, Punjab, IN
3 MM Medical College & Hospital Kumarhatti-Solan HP, IN
Source
International Journal of Medical and Dental Sciences, Vol 2, No 2 (2013), Pagination: 239-241Abstract
Male child preference is a well known phenomenon in Indian society. There are various drugs and techniques used to achieve this target, even though these are illegal and punishable. Women desirous of male child try to procure these drugs which are supposed to help in sex selection. These secretly procured drugs can cause congenital defects in the fetus due to the fact that these drugs are always administered during first trimester - the most vulnerable period for the fetus. There are many drugs, whose teratogenic potential is already known. But in the absence of enough data and lack of clinical trial studies in pregnant women, we don't really know about many drugs, which are necessary for various medical conditions during pregnancy. On top of that these so called sex selection drugs add to an unhealthy practice leading to many more probable congenital anomalies. It is the need of the hour that proper data is collected about all such drugs and their implications is studied on fetus. Due to secret prescriptions, it may be difficult to ban such drugs, but public awareness and health education about congenital anomalies caused by such drugs is probably the only way to fight this menace.Full Text
- Effect of Antihypertensive Drugs on Quality of Life in Elderly Patients
Authors
1 Genesis Institute of Dental Sciences and Research Ferozepur, Punjab, IN
2 Punjab Institute of Medical Sciences Jalandhar, Punjab, IN
3 Christian medical college &hospital Ludhiana, Punjab, IN
Source
International Journal of Medical and Dental Sciences, Vol 1, No 1 (2012), Pagination: 9-13Abstract
The use of drugs to increase human happiness and to improve the quality of life physically, mentally and socioeconomically is a serious matter of concern. Chronic disabling conditions become common in old age and affect the quality of life. Quality of life (QOL) is an important measure of health care, which measures the gap between expectations and achievements. Effect of Drug use on quality of life in elderly Indian population with hypertension was studied using Mc Master Health Index. The study population was divided into test group (hypertensive patients on regular treatment) and control group (Not on any treatment or on treatment for less than 3 months). All three parameters of QOL namely physical, emotional and social were studied using Mc Master Health Index questionnaire. The results were statistically compared using ANOVA and chi square. Our results point toward better overall QOL in patients on regular treatment.Keywords
Quality of Life, Hypertension, Elderly.Full Text
- Clinical Profile of Hepatorenal SyndromeClinical Profile of Hepatorenal Syndrome:A Prospective Study
Authors
1 Ludhiana, IN
2 Punjab Institute of Medical Sciences Jalandhar, Punjab, IN
3 Dayanand medical college and hospital Ludhiana, Punjab, IN
Source
International Journal of Medical and Dental Sciences, Vol 5, No 2 (2016), Pagination: 1241-1246Abstract
Background: Hepatorenal syndrome is the development of renal failure in patients with advanced liver cirrhosis, occasionally fulminant hepatitis, who have portal hypertension and ascitis in the absence of some other kidney disease.
Objective: To study the clinical profile of hepatorenal syndrome.
Methods: All patients of chronic liver disease with renal involvement were studied and patients fulfilling the criteria of hepatorenal syndrome were recruited in the study. The etiology, clinical presentation, morbidity and outcome of patients were recorded. Various variables were studied between survivor group and non survivor group to detect possible predictors of non survival in hepatorenal syndrome. The data was analyzed using SPSS software.
Results: 42 patients of hepatorenal syndrome were clinically evaluated. 95% were males and 5% females with mean age of 50.29±8.87 in survivor group and 45.92±10.1 in non survivor group. High level of serum bilirubin, hepatic encephalopathy, decreased level of albumin, hyponatremia and coagulopathy were significant in non survivor group as compared to survivor group.
Conclusion: The poor prognostic factors were found to be ascites, severe jaundice, hepatic encephalopathy, alcohol abuse, hypoalbuminemia, progressive renal failure and child pugh score greater than 10. Thus hepatorenal syndrome is decompensated cirrhosis which needs judicious treatment especially using terlipressin and albumin.
Keywords
Hepatorenal Syndrome, Profile, Jaundice, Child Pugh Score, Ascitis, Albumin.Full Text
References
- Arroyo V, Gines P, Jimenez W. Renal dysfunction in cirrhosis. In: Bricher J, Benhamou J, McIntyre N, Rizzetto M, Rodes J, editors. Oxford textbook of clinical hepatology. 2nd ed. England: Oxford university press; 1999.p.733-61.
- Epstein M. Hepatorenal syndrome. Emerging perspectives of pathophysiology and therapy. J Am Soc Nephro 1994;14:1735-53.
- Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 1993;105:229-36.
- Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56(9):1310–8.
- Lata J. Hepatorenal syndrome. World Journal of Gastroenterology 2012;36(18):4978–84.
- Butt AK, Khan AA, Alam A, Shah SW, Shafqat F, Naqvi AB. Predicting hospital mortality in cirrhotic patients: comparision of child Pugh and acute physiology, age and chronic health evaluation scoring systems. Am J Gastroenterol 1998;93(12):2489-75.
- Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Hepatology 1987;7:122-8.
- Salerno F, Borroni G, Moser P, Badalamenti S, Cassara L, Maggi A, et al. Survival and prognostic factors of cirrhotic patients with ascitis: a study of 134 out patients. Am J Gastroenterol 1993;88:514-19.
- Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features and outcome in a tertiary care center. Am J Gastroenterol 2002;97(8):1868-70.
- Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barriere E, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. Gastrenterol Hepato 2002;17(18):882-8.
- Moreau R, Durand F, Poynard T. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;6:2160–1.
- New Ray of Hope for Psychosis in Parkinsons:Pimavanserin
Authors
1 Department of Pharmacology, Punjab Institute of Medical Sciences, Jalandhar, Punjab, IN
Source
International Journal of Medical and Dental Sciences, Vol 5, No 2 (2016), Pagination: 1347-1349Abstract
Parkinson's disease is often associated with hallucinations and psychosis. Till now typical and atypical antipsychotics (Clozapine&Quetiapine) are being used to manage these symptoms. Recently US FDA has approved a new drug Pimavanserin for the treatment of hallucination and delusion associated with parkinson's disease psychosis in a dose of 34 mg.Keywords
Hallucinations, Delusions, Psychosis, Parkinsonism, Pimavanserin.Full Text
References
- Olanow CW, Schapira AHV, Obeso JA. Parkinsons disease and other movement disorders. In: Kasper, Fauci, Hauser, Longo Jameson, Loscalzo, editors. Harrisons principles of internal medicine 19th ed. New York: Mc Graw Hill Education; 2015.p.2617.
- Highlights of prescribing information. Available at: www.access data.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf. Accessed on 15.05.2016.
- Cummings J, Isaacson S, Mills R, Williams H, Chi-burris K, Corbett A, et al. Pimavanserin for patients with parkinson’s disease psychosis: a randomised, placebo- controlled phase 3 trial. The Lancet. http://dx.doi.org/10.1016/S0140-6736(13)62157-1.